90Y Basiliximab

N/A

Report date: 2025/09/09 15:00:33

Base Information

Drug Name90Y Basiliximab
Drug Alias NameYttrium Y 90 Basiliximab钇[90Y]-DOTA-巴利昔单抗Yttrium Y 90-DOTA-Basiliximabyttrium Y 90-labeled basiliximabYttrium - 90 Basiliximab +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsMyelodysplastic SyndromesLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A